CytRx presents Aldoxorubicin clinical data at ESMO 2012 Congress

CytRx Corporation announced that favorable data from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly INNO-206) in patients with advanced soft tissue sarcoma was presented today at the Sarcoma Poster-Discussion Session at the ESMO 2012 Congress in Vienna, Austria. The data from the aldoxorubicin Phase 1b/2 clinical trial showed clinical benefit with aldoxorubicin at the maximum tolerated dose in 10 of 13 evaluable patients with relapsed or refractory soft tissue sarcoma.

View Comments (0)